

GRANT AGREEMENT

<u>BETWEEN</u>

Desire Collen Stichting - Private Stichting (« DCS »)

With registered office at Groot Begijnhof 60/001, 3000 Leuven, company number BE 0598.907.593 and duly represented by Désiré COLLEN, Director – « The Grantor »

<u>AND</u>

Louis-Jeantet Foundation (« LJF »),

With registered office at Chemin Rieu 17, 1208 Genève and duly represented by Jean-Louis CARPENTIER, President - « The Grantee »

Jointly referred to as « The parties »

IT WAS AGREED THAT

DCS will enter into a grant (« The Grant ») in the amount of up to CHF 1,800,000 to LIF for the following purposes («The Project »):

The installation of a European Jeantet-Collen Prize for Translational Medicine for a 3-year period 2019 – 2021 inclusive

- The Prize must be awarded for translational medicine/research.
- One or more awardee(s) will be proposed by the Jury of the LJF to a committee that will be composed of 2-3 experts designated by DCS from VIB/KU Leuven or other institutions (hereafter the « DCS Expert Committee ») for their evaluation and potential approval.
- The Louis-Jeantet Prize and the Jeantet-Collen Prize will be for equal amounts (planned CHF 500,000).
- The Prize will be awarded annually, except if no nominee is proposed by the LIF to the DCS Expert Committee or no candidate is approved by the DCS Expert Committee.
- The Jeantet-Collen Prize will be announced in a subheading of the annual call for nominations for the Louis-Jeantet Prize, except for the first 2019 Prize.

Financing of the "Jeantet-Collen Prize":

- The endowment for the Jeantet-Collen Prize will be financed by the DCS or any other fund designated by Désiré Collen.
- This same financing body will finance CHF 100,000 per year to contribute to the expenses of the Jury of the LJF, even in the absence of the Jeantet-Collen Prize attribution.





Duration of agreement:

- This convention is for an initial period of 3 years
- The first call for nominations with the subheading for the Jeantet-Collen Prize will be for the 2020 Prize. For 2019, the President of the Jury (presently Sir Paul Nurse) will, confidentially, communicate to DCS the recipient who could qualify for the Jeantet-Collen Prize, if any. DCS will present, confidentially, the contemplated awardee to the DCS Expert Committee for their final approval.

The Grant is conditional upon the following terms and conditions:

1. Purpose

The Grant may only be used for the purposes described above.

2. Payment

The Grant will be made in three (3) payments, payable annually on or before December 31 2018, December 31 2019 and December 31 2020. Each payment will comprise CHF 100,000 contribution to expenses plus CHF 500,000 if a Jeantet-Collen Prize for Translational Medicine is awarded that year.

3. Independence of the Parties

Both Grantor and Grantee affirm that this Agreement does not, in any way, compromise the Grantee's scientific and research freedom and the Grantor shall have no responsibility in administering the Grant or directly overseeing the Projects.

4. Severance

If any provision of the agreement contained in this letter shall be found by any court of administrative body of competent jurisdiction to be invalid or unenforceable, such invalidity or unenforceability shall not affect the other provisions of this letter, which shall remain in full force and effect.

5. Governing Law and jurisdiction

The agreement is governed and shall be construed in accordance with the substantive laws of Switzerland. All disputes arising out of, in connection with or relating to this Agreement and which the Parties are unable to settle amicably shall be subject to the exclusive jurisdiction of the courts of Geneva, Switzerland.

6. Contact Persons

For DCS:

Desire Collen, 16, Queen's Gate Place Flat1, London SW7 5NY, UK

For LJF

Jean-Louis Carpentier, Chemin Rieu 17, 1208 Genève, Switzerland

Signed and executed in 2 copies, in Geneva, on 14 December 2018

For DCS

D. Collen

For UF

J.-L. Carpentier

J. A. Schifferli

Director

President

Vice-President